Copyright Reports & Markets. All rights reserved.

Global Acute Intermittent Porphyria Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Acute Intermittent Porphyria Drugs
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Acute Intermittent Porphyria Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 350mg
    • 1.3.3 313mg
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Acute Intermittent Porphyria Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital
    • 1.4.3 Pharmacy
  • 1.5 Global Acute Intermittent Porphyria Drugs Market Size & Forecast
    • 1.5.1 Global Acute Intermittent Porphyria Drugs Consumption Value (2019 & 2023 & 2030)
    • 1.5.2 Global Acute Intermittent Porphyria Drugs Sales Quantity (2019-2030)
    • 1.5.3 Global Acute Intermittent Porphyria Drugs Average Price (2019-2030)

2 Manufacturers Profiles

  • 2.1 Recordati Rare Diseases
    • 2.1.1 Recordati Rare Diseases Details
    • 2.1.2 Recordati Rare Diseases Major Business
    • 2.1.3 Recordati Rare Diseases Acute Intermittent Porphyria Drugs Product and Services
    • 2.1.4 Recordati Rare Diseases Acute Intermittent Porphyria Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Recordati Rare Diseases Recent Developments/Updates

3 Competitive Environment: Acute Intermittent Porphyria Drugs by Manufacturer

  • 3.1 Global Acute Intermittent Porphyria Drugs Sales Quantity by Manufacturer (2019-2024)
  • 3.2 Global Acute Intermittent Porphyria Drugs Revenue by Manufacturer (2019-2024)
  • 3.3 Global Acute Intermittent Porphyria Drugs Average Price by Manufacturer (2019-2024)
  • 3.4 Market Share Analysis (2023)
    • 3.4.1 Producer Shipments of Acute Intermittent Porphyria Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
    • 3.4.2 Top 3 Acute Intermittent Porphyria Drugs Manufacturer Market Share in 2023
    • 3.4.2 Top 6 Acute Intermittent Porphyria Drugs Manufacturer Market Share in 2023
  • 3.5 Acute Intermittent Porphyria Drugs Market: Overall Company Footprint Analysis
    • 3.5.1 Acute Intermittent Porphyria Drugs Market: Region Footprint
    • 3.5.2 Acute Intermittent Porphyria Drugs Market: Company Product Type Footprint
    • 3.5.3 Acute Intermittent Porphyria Drugs Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Acute Intermittent Porphyria Drugs Market Size by Region
    • 4.1.1 Global Acute Intermittent Porphyria Drugs Sales Quantity by Region (2019-2030)
    • 4.1.2 Global Acute Intermittent Porphyria Drugs Consumption Value by Region (2019-2030)
    • 4.1.3 Global Acute Intermittent Porphyria Drugs Average Price by Region (2019-2030)
  • 4.2 North America Acute Intermittent Porphyria Drugs Consumption Value (2019-2030)
  • 4.3 Europe Acute Intermittent Porphyria Drugs Consumption Value (2019-2030)
  • 4.4 Asia-Pacific Acute Intermittent Porphyria Drugs Consumption Value (2019-2030)
  • 4.5 South America Acute Intermittent Porphyria Drugs Consumption Value (2019-2030)
  • 4.6 Middle East and Africa Acute Intermittent Porphyria Drugs Consumption Value (2019-2030)

5 Market Segment by Type

  • 5.1 Global Acute Intermittent Porphyria Drugs Sales Quantity by Type (2019-2030)
  • 5.2 Global Acute Intermittent Porphyria Drugs Consumption Value by Type (2019-2030)
  • 5.3 Global Acute Intermittent Porphyria Drugs Average Price by Type (2019-2030)

6 Market Segment by Application

  • 6.1 Global Acute Intermittent Porphyria Drugs Sales Quantity by Application (2019-2030)
  • 6.2 Global Acute Intermittent Porphyria Drugs Consumption Value by Application (2019-2030)
  • 6.3 Global Acute Intermittent Porphyria Drugs Average Price by Application (2019-2030)

7 North America

  • 7.1 North America Acute Intermittent Porphyria Drugs Sales Quantity by Type (2019-2030)
  • 7.2 North America Acute Intermittent Porphyria Drugs Sales Quantity by Application (2019-2030)
  • 7.3 North America Acute Intermittent Porphyria Drugs Market Size by Country
    • 7.3.1 North America Acute Intermittent Porphyria Drugs Sales Quantity by Country (2019-2030)
    • 7.3.2 North America Acute Intermittent Porphyria Drugs Consumption Value by Country (2019-2030)
    • 7.3.3 United States Market Size and Forecast (2019-2030)
    • 7.3.4 Canada Market Size and Forecast (2019-2030)
    • 7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe

  • 8.1 Europe Acute Intermittent Porphyria Drugs Sales Quantity by Type (2019-2030)
  • 8.2 Europe Acute Intermittent Porphyria Drugs Sales Quantity by Application (2019-2030)
  • 8.3 Europe Acute Intermittent Porphyria Drugs Market Size by Country
    • 8.3.1 Europe Acute Intermittent Porphyria Drugs Sales Quantity by Country (2019-2030)
    • 8.3.2 Europe Acute Intermittent Porphyria Drugs Consumption Value by Country (2019-2030)
    • 8.3.3 Germany Market Size and Forecast (2019-2030)
    • 8.3.4 France Market Size and Forecast (2019-2030)
    • 8.3.5 United Kingdom Market Size and Forecast (2019-2030)
    • 8.3.6 Russia Market Size and Forecast (2019-2030)
    • 8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific

  • 9.1 Asia-Pacific Acute Intermittent Porphyria Drugs Sales Quantity by Type (2019-2030)
  • 9.2 Asia-Pacific Acute Intermittent Porphyria Drugs Sales Quantity by Application (2019-2030)
  • 9.3 Asia-Pacific Acute Intermittent Porphyria Drugs Market Size by Region
    • 9.3.1 Asia-Pacific Acute Intermittent Porphyria Drugs Sales Quantity by Region (2019-2030)
    • 9.3.2 Asia-Pacific Acute Intermittent Porphyria Drugs Consumption Value by Region (2019-2030)
    • 9.3.3 China Market Size and Forecast (2019-2030)
    • 9.3.4 Japan Market Size and Forecast (2019-2030)
    • 9.3.5 Korea Market Size and Forecast (2019-2030)
    • 9.3.6 India Market Size and Forecast (2019-2030)
    • 9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
    • 9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America

  • 10.1 South America Acute Intermittent Porphyria Drugs Sales Quantity by Type (2019-2030)
  • 10.2 South America Acute Intermittent Porphyria Drugs Sales Quantity by Application (2019-2030)
  • 10.3 South America Acute Intermittent Porphyria Drugs Market Size by Country
    • 10.3.1 South America Acute Intermittent Porphyria Drugs Sales Quantity by Country (2019-2030)
    • 10.3.2 South America Acute Intermittent Porphyria Drugs Consumption Value by Country (2019-2030)
    • 10.3.3 Brazil Market Size and Forecast (2019-2030)
    • 10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa

  • 11.1 Middle East & Africa Acute Intermittent Porphyria Drugs Sales Quantity by Type (2019-2030)
  • 11.2 Middle East & Africa Acute Intermittent Porphyria Drugs Sales Quantity by Application (2019-2030)
  • 11.3 Middle East & Africa Acute Intermittent Porphyria Drugs Market Size by Country
    • 11.3.1 Middle East & Africa Acute Intermittent Porphyria Drugs Sales Quantity by Country (2019-2030)
    • 11.3.2 Middle East & Africa Acute Intermittent Porphyria Drugs Consumption Value by Country (2019-2030)
    • 11.3.3 Turkey Market Size and Forecast (2019-2030)
    • 11.3.4 Egypt Market Size and Forecast (2019-2030)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
    • 11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics

  • 12.1 Acute Intermittent Porphyria Drugs Market Drivers
  • 12.2 Acute Intermittent Porphyria Drugs Market Restraints
  • 12.3 Acute Intermittent Porphyria Drugs Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Acute Intermittent Porphyria Drugs and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Acute Intermittent Porphyria Drugs
  • 13.3 Acute Intermittent Porphyria Drugs Production Process
  • 13.4 Acute Intermittent Porphyria Drugs Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Acute Intermittent Porphyria Drugs Typical Distributors
  • 14.3 Acute Intermittent Porphyria Drugs Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Acute Intermittent Porphyria Drugs market size was valued at USD 50 million in 2023 and is forecast to a readjusted size of USD 56 million by 2030 with a CAGR of 1.7% during review period.
    Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deaminase. It is the most common of the acute porphyrias.
    Panhematin (hemin) is a medication used to treat acute porphyria, a rare genetic disorder that affects heme production. Its effectiveness in managing acute porphyria attacks and reducing symptoms has driven market growth. The rarity of the condition and limited treatment options contribute to its niche status. However, challenges include the need for careful monitoring and potential side effects. The market competition is relatively small, as Panhematin remains a specialized therapy.
    The Global Info Research report includes an overview of the development of the Acute Intermittent Porphyria Drugs industry chain, the market status of Hospital (350mg, 313mg), Pharmacy (350mg, 313mg), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Acute Intermittent Porphyria Drugs.
    Regionally, the report analyzes the Acute Intermittent Porphyria Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Acute Intermittent Porphyria Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Acute Intermittent Porphyria Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Acute Intermittent Porphyria Drugs industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (Units), revenue generated, and market share of different by Type (e.g., 350mg, 313mg).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Acute Intermittent Porphyria Drugs market.
    Regional Analysis: The report involves examining the Acute Intermittent Porphyria Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Acute Intermittent Porphyria Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Acute Intermittent Porphyria Drugs:
    Company Analysis: Report covers individual Acute Intermittent Porphyria Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Acute Intermittent Porphyria Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Pharmacy).
    Technology Analysis: Report covers specific technologies relevant to Acute Intermittent Porphyria Drugs. It assesses the current state, advancements, and potential future developments in Acute Intermittent Porphyria Drugs areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Acute Intermittent Porphyria Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Acute Intermittent Porphyria Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
    Market segment by Type
    350mg
    313mg
    Market segment by Application
    Hospital
    Pharmacy
    Major players covered
    Recordati Rare Diseases
    Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Acute Intermittent Porphyria Drugs product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Acute Intermittent Porphyria Drugs, with price, sales, revenue and global market share of Acute Intermittent Porphyria Drugs from 2019 to 2024.
    Chapter 3, the Acute Intermittent Porphyria Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Acute Intermittent Porphyria Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
    Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Acute Intermittent Porphyria Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
    Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Acute Intermittent Porphyria Drugs.
    Chapter 14 and 15, to describe Acute Intermittent Porphyria Drugs sales channel, distributors, customers, research findings and conclusion.

    Buy now